$Phase II Trial of Amsacrine Plus Intermediate-dose Ara-C (IDAC) with or without Etoposide as Salvage Therapy for Refractory or Relapsed Acute Leukemia$

Phase II Trial of Amsacrine Plus Intermediate-dose Ara-C (IDAC) with or without Etoposide as Salvage Therapy for Refractory or Relapsed Acute Leukemia

Objective: The current trial attempted to evaluate the efficacy and toxicity of a salvage therapy consisting of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide for acute leukemia patients in refractory or relapsed states. Methods: A total of 51 patients with refractory or rel...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Japanese journal of clinical oncology 2005-10, Vol.35 (10), p.612-616
Hauptverfasser:	Sung, Woo Jin, Kim, Dong Hwan, Sohn, Sang Kyun, Kim, Jong Gwang, Baek, Jin Ho, Jeon, Seok Bong, Moon, Joon Ho, Ahn, Byung Min, Lee, Kyu Bo
Format:	Artikel
Sprache:	eng
Schlagworte:	acute leukemia Adolescent Adult Aged amsacrine Amsacrine - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cytarabine - administration & dosage Diarrhea - chemically induced Drug Administration Schedule etoposide Etoposide - administration & dosage Female Humans intermediate-dose Ara-C Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - mortality Male Middle Aged Nausea - chemically induced Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality Remission Induction Salvage Therapy Survival Rate Treatment Outcome Vomiting, Anticipatory - etiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!